Skip to main content

Advertisement

SpringerLink
Log in

Anti-infective antibodies: finding the path forward

  • News Feature
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

Despite growing commercial interest in antimicrobial strategies that rely on antibodies, recent clinical trial failures suggest they are a work in progress.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: License to kill.

CNRI/Photo Researchers, Inc.

References

  1. Eash, S. Pharmacor, Infectious Disease, Study #2 2006 Decision Resources, Waltham, MA (2006) in press.

  2. Projan, S.J., Nesin, M. & Dunman, P.M. Curr. Opin. Pharmacol. 6, 473–479 (2006).

    Article  CAS  Google Scholar 

  3. Pirofski, L.A. & Casadevall, A. Curr. Opin. Microbiol. 9, 489–495 (2006).

    Article  CAS  Google Scholar 

  4. Casadevall, A. Clin. Infect. Dis. 42, 1414–1416 (2006).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. San Francisco

    Monya Baker

Authors
  1. Monya Baker
    View author publications

    You can also search for this author in PubMed Google Scholar

Related links

Related links

Web links

Inhibitex

Elusys Therapeutics

Nabi Biopharmaceuticals

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baker, M. Anti-infective antibodies: finding the path forward. Nat Biotechnol 24, 1491–1493 (2006). https://doi.org/10.1038/nbt1206-1491

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1206-1491

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation